News
54m
Xilio Therapeutics Announces Pipeline And Business Updates And Second Quarter 2025 Financial Results
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a m ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback